A Registry for People With Lung Cancer
NCT06424327
Lung Cancer, Lung Cancer Stage I
Tucson, Arizona, United States
View Trial DetailsNCT Number: NCT06692972
Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. This study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. It will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.
Interested in participating?
Request Info18 year and older
All sexes
Observational
China-Japan Friendship Hospital, Beijing, Beijing Municipality, China
This study intends to retrospectively screen and include participants according to inclusion and exclusion criteria, and collect the clinical data of participants by previous medical records. Imaging tools will be used to quantify changes in the spatial location, diameter and volume of target lesions to evaluate tumor regression rate and radiotherapy efficacy, and to explore tumor regression pattern and establish model. In addition, the relationship between tumor regression rate, incidence of adverse radiation events, prognosis and related factors will be analysed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
:
Time frame: Within 1 year after completion of radiotherapy.
(1- post-treatment tumor volume/baseline tumor volume)×100%
Time frame: Within 1 year after completion of radiotherapy.
It refers to the proportion of patients who experience a complete or partial remission of tumors in response to treatment, as determined by RECIST criterion.
Time frame: Within 1 year after completion of radiotherapy.
It refers to the proportion of patients who experience an objective response (complete or partial remission) or stable disease in response to treatment, as determined by RECIST criterion.
Time frame: From the start of treatment until the time of disease progression or death, assessed up to 120 months.
It's calculated from the start of treatment until the time of disease progression or the patient's death, whichever comes first.
Time frame: From the start of treatment until the time of death, assessed up to 120 months.
It measures the length of time from the start of treatment until the death of the patient from any cause.
Time frame: Within 1 year after completion of radiotherapy.
It refers to the frequency of treatment related adverse event.
Contact information is provided by the study sponsor or research team.
China-Japan Friendship Hospital
Other
Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06424327
Lung Cancer, Lung Cancer Stage I
Tucson, Arizona, United States
View Trial DetailsNCT00001823
Bladder Cancer, Colonic Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT00034216
Breast Cancer, Breast Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05401110
Bronchial Neoplasms, Carcinoma, Bronchogenic
Beverly Hills, California, United States
View Trial Details